NovoCure (NVCR) Receivables (2014 - 2026)

NovoCure (NVCR) has reported Receivables for 13 consecutive years, with $106.8 million the latest figure, recorded in Q2 2026.

• Quarterly Receivables rose 10.26% year-over-year to $106.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $106.8 million (up 10.26% YoY) and the FY2025 annual result came in at $97.2 million, up 21.6% from the prior year.
• Receivables improved to $106.8 million in Q2 2026 per NVCR's latest filing, from $101.5 million in the prior quarter.
• Over the last five years, Receivables for NVCR reached as high as $106.8 million in Q2 2026 and fell as low as $26.9 million in Q4 2023.
• A 5-year average of $77.3 million and a median of $81.2 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables plunged 69.91% — and 2025, when it surged 138.36%.
• Year by year, Receivables stood at $28.2 million in 2022, then retreated by 4.34% to $26.9 million in 2023, then jumped by 51.47% to $40.8 million in 2024, then soared by 138.36% to $97.2 million in 2025, then increased by 9.85% to $106.8 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $106.8 million, $101.5 million, and $97.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.